The RAMP-201 trial showed the combination of Avutometinib and Defactinib achieved a 25% response rate even in patients who had progressed on or were intolerant of prior single-agent MEK inhibitors. This establishes the doublet as an effective subsequent line of therapy in a resistant population.
The landmark GY019 trial confirmed that letrozole alone is inferior to the standard of chemotherapy followed by letrozole maintenance. This was a surprising result for a chemo-resistant tumor, solidifying the need for chemotherapy in the adjuvant setting despite its limited effectiveness.
While initial response rates are similar between the Avutometinib/Defactinib doublet and single-agent Trametinib, the doublet provides double the progression-free survival (PFS). Its remarkable duration of response (over 30 months) indicates superior long-term disease control.
Unlike many cancers, younger patients (in their 20s-30s) with low-grade serous ovarian cancer have a worse prognosis than older patients. This is because they are less likely to carry a KRAS mutation, making them less responsive to highly effective targeted therapies.
This cancer is a "low-shedding" tumor, making circulating tumor DNA (ctDNA) difficult to detect. A key study found only 32% of patients with measurable disease had detectable ctDNA, and the concordance for KRAS status with tumor sequencing was only 44%, mandating tissue-based testing.
The doublet's unique dosing schedule (twice-weekly pills for three weeks, then one week off) is crucial for its long-term success. This "recovery week" per cycle is thought to reduce cumulative toxicity, allowing patients to stay on this highly effective therapy for extended periods.
